Literature DB >> 605378

Mutagen-induced diploid human lymphoblast variants containing altered hypoxanthine guanine phosphoribosyl transferase.

J Epstein, A Leyva, W N Kelley, J W Littlefield.   

Abstract

The human lymphoblast line MGL8 was treated with HAT and subsequently "mutagenized" with EMS (200 microgram/ml) to give 15% survival, and 6-thioguanine-resistant cells were selected by cloning in soft agarose containing the drug (1 microgram/ml). Eighteen sublines of independently derived resistant clones were isolated and studied in detail. One subline had a low residual HGPRT activity of about 1% of the parental cells. The HGPRT of this subline had a higher Km for PRPP, was more sensitive to heat, and was degraded faster by trypsin than the enzyme in extracts of MGL8 cells. This resistant subline and three others contained CRM levels of 1--38%, compared to the wild-type, so they probably represent true structural mutants of the HGPRT gene. All the variants maintained the karyotype of the parental line (46, XY, 6p-).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 605378     DOI: 10.1007/bf01551810

Source DB:  PubMed          Journal:  Somatic Cell Genet        ISSN: 0098-0366


  4 in total

1.  Isolation of diploid human lymphoblast mutants presumably homozygous for ouabain resistance.

Authors:  W N Choy; J W Littlefield
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

2.  Purine-resistant Drosophila melanogaster result from mutations in the adenine phosphoribosyltransferase structural gene.

Authors:  D H Johnson; T B Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

3.  Human T cell hybridomas secreting factors for IgA-specific help, polyclonal B cell activation, and B cell proliferation.

Authors:  L Mayer; S M Fu; H G Kunkel
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

4.  Generation of functional human T cell hybrids.

Authors:  O Irigoyen; P V Rizzolo; Y Thomas; L Rogozinski; L Chess
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.